Miguel Debono1, Robert F Harrison2, Rita Chadarevian3, Carole Gueroult3, Jean-Louis Abitbol3, John Newell-Price1. 1. Academic Unit of Endocrinology, University of Sheffield, Sheffield S10 2TN, United Kingdom. 2. Department of Automatic Control and Systems Engineering, University of Sheffield S10 2TN, Sheffield, United Kingdom. 3. HRA Pharma, 14/16 rue des Petits Hôtels 75 010 Paris, France.
Abstract
Context: Adrenal incidentalomas (AIs) are found commonly on axial imaging. Around 30% exhibit autonomous cortisol secretion (ACS) associated with increased cardiovascular events and death. Objective: We hypothesized that AI/ACS patients have an abnormal cortisol rhythm that could be reversed by use of carefully timed short-acting cortisol synthesis blockade, with improvement in cardiovascular disease markers. Design, Setting, and Participants: In a phase 1/2a, prospective study (Eudract no. 2012-002586-35), we recruited six patients with AI/ACS and two control groups of six sex-, age-, and body mass index-matched individuals: (1) patients with AI and no ACS (AI/NoACS) and (2) healthy volunteers with no AI [healthy controls (HC)]. Twenty-four-hour circadian cortisol analysis was performed to determine any differences between groups and timing of intervention for cortisol lowering using the 11β-hydroxylase inhibitor metyrapone. Circadian profiles of serum interleukin-6 (IL-6) were assessed. Results: Serum cortisol levels in group AI/ACS were significantly higher than both group AI/NoACS and group HC from 6 pm to 10 pm [area under the curve (AUC) difference: 0.81 nmol/L/h; P = 0.01] and from 10 pm to 2 am (AUC difference: 0.86 nmol/L/h; P < 0.001). In light of these findings, patients with ACS received metyrapone 500 mg at 6 pm and 250 mg at 10 pm, and cortisol rhythms were reassessed. Postintervention evening serum cortisol was lowered, similar to controls [6 pm to 10 pm (AUC difference: -0.06 nmol/L/h; P = 0.85); 10 pm to 2 am (AUC difference: 0.10 nmol/L/h; P = 0.76)]. Salivary cortisone showed analogous changes. IL-6 levels were elevated before treatment [10 pm to 2 pm (AUC difference: 0.42 pg/mL/h; P = 0.01)] and normalized post treatment. Conclusions: In AI/ACS, the evening and nocturnal cortisol exposure is increased. Use of timed evening doses of metyrapone resets the cortisol rhythm to normal. This unique treatment paradigm is associated with a reduction in the cardiovascular risk marker IL-6.
Context: Adrenal incidentalomas (AIs) are found commonly on axial imaging. Around 30% exhibit autonomous cortisol secretion (ACS) associated with increased cardiovascular events and death. Objective: We hypothesized that AI/ACS patients have an abnormal cortisol rhythm that could be reversed by use of carefully timed short-acting cortisol synthesis blockade, with improvement in cardiovascular disease markers. Design, Setting, and Participants: In a phase 1/2a, prospective study (Eudract no. 2012-002586-35), we recruited six patients with AI/ACS and two control groups of six sex-, age-, and body mass index-matched individuals: (1) patients with AI and no ACS (AI/NoACS) and (2) healthy volunteers with no AI [healthy controls (HC)]. Twenty-four-hour circadian cortisol analysis was performed to determine any differences between groups and timing of intervention for cortisol lowering using the 11β-hydroxylase inhibitor metyrapone. Circadian profiles of serum interleukin-6 (IL-6) were assessed. Results: Serum cortisol levels in group AI/ACS were significantly higher than both group AI/NoACS and group HC from 6 pm to 10 pm [area under the curve (AUC) difference: 0.81 nmol/L/h; P = 0.01] and from 10 pm to 2 am (AUC difference: 0.86 nmol/L/h; P < 0.001). In light of these findings, patients with ACS received metyrapone 500 mg at 6 pm and 250 mg at 10 pm, and cortisol rhythms were reassessed. Postintervention evening serum cortisol was lowered, similar to controls [6 pm to 10 pm (AUC difference: -0.06 nmol/L/h; P = 0.85); 10 pm to 2 am (AUC difference: 0.10 nmol/L/h; P = 0.76)]. Salivary cortisone showed analogous changes. IL-6 levels were elevated before treatment [10 pm to 2 pm (AUC difference: 0.42 pg/mL/h; P = 0.01)] and normalized post treatment. Conclusions: In AI/ACS, the evening and nocturnal cortisol exposure is increased. Use of timed evening doses of metyrapone resets the cortisol rhythm to normal. This unique treatment paradigm is associated with a reduction in the cardiovascular risk marker IL-6.
Authors: Olaf M Dekkers; Erzsébet Horváth-Puhó; Jens Otto L Jørgensen; Suzanne C Cannegieter; Vera Ehrenstein; Jan P Vandenbroucke; Alberto M Pereira; Henrik Toft Sørensen Journal: J Clin Endocrinol Metab Date: 2013-03-26 Impact factor: 5.958
Authors: Diana Lopez; Miguel Angel Luque-Fernandez; Amy Steele; Gail K Adler; Alexander Turchin; Anand Vaidya Journal: Ann Intern Med Date: 2016-08-02 Impact factor: 25.391
Authors: Miguel Debono; Robert F Harrison; Martin J Whitaker; David Eckland; Wiebke Arlt; Brian G Keevil; Richard J Ross Journal: J Clin Endocrinol Metab Date: 2016-01-26 Impact factor: 5.958
Authors: Regina Belokovskaya; Aarti Ravikumar; Dushyanthy Arumugam; Sudeh Izadmehr; Gillian M Goddard; Eliza B Geer; Alice C Levine Journal: Endocr Pract Date: 2019-05-09 Impact factor: 3.701
Authors: Robert F Harrison; Miguel Debono; Martin J Whitaker; Brian G Keevil; John Newell-Price; Richard J Ross Journal: J Clin Endocrinol Metab Date: 2019-03-01 Impact factor: 5.958